ATARA BIOTHERAPEUTICS INC (ATRA) Fundamental Analysis & Valuation

NASDAQ:ATRA • US0465132068

Current stock price

5.01 USD
+0.11 (+2.24%)
Last:

This ATRA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. ATRA Profitability Analysis

1.1 Basic Checks

  • In the past year ATRA was profitable.
  • In the past year ATRA has reported a negative cash flow from operations.
  • In the past 5 years ATRA reported 4 times negative net income.
  • In the past 5 years ATRA always reported negative operating cash flow.
ATRA Yearly Net Income VS EBIT VS OCF VS FCFATRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100M -200M -300M

1.2 Ratios

  • The Return On Assets of ATRA (161.54%) is better than 100.00% of its industry peers.
  • ATRA has a better Return On Invested Capital (781.69%) than 100.00% of its industry peers.
Industry RankSector Rank
ROA 161.54%
ROE N/A
ROIC 781.69%
ROA(3y)-27.86%
ROA(5y)-43.38%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ATRA Yearly ROA, ROE, ROICATRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 -500

1.3 Margins

  • ATRA's Profit Margin of 27.07% is amongst the best of the industry. ATRA outperforms 93.80% of its industry peers.
  • ATRA has a Operating Margin of 43.53%. This is amongst the best in the industry. ATRA outperforms 98.64% of its industry peers.
  • The Gross Margin of ATRA (82.44%) is better than 85.08% of its industry peers.
Industry RankSector Rank
OM 43.53%
PM (TTM) 27.07%
GM 82.44%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATRA Yearly Profit, Operating, Gross MarginsATRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. ATRA Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so ATRA is creating value.
  • ATRA has more shares outstanding than it did 1 year ago.
  • ATRA has less shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, ATRA has a worse debt to assets ratio.
ATRA Yearly Shares OutstandingATRA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
ATRA Yearly Total Debt VS Total AssetsATRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • Based on the Altman-Z score of -125.10, we must say that ATRA is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -125.10, ATRA is doing worse than 95.16% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -125.1
ROIC/WACC110.41
WACC7.08%
ATRA Yearly LT Debt VS Equity VS FCFATRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M

2.3 Liquidity

  • A Current Ratio of 0.82 indicates that ATRA may have some problems paying its short term obligations.
  • ATRA has a Current ratio of 0.82. This is amonst the worse of the industry: ATRA underperforms 89.34% of its industry peers.
  • A Quick Ratio of 0.82 indicates that ATRA may have some problems paying its short term obligations.
  • ATRA has a worse Quick ratio (0.82) than 88.76% of its industry peers.
Industry RankSector Rank
Current Ratio 0.82
Quick Ratio 0.82
ATRA Yearly Current Assets VS Current LiabilitesATRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. ATRA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 124.06% over the past year.
  • Looking at the last year, ATRA shows a decrease in Revenue. The Revenue has decreased by -6.33% in the last year.
  • ATRA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 23.85% yearly.
EPS 1Y (TTM)124.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.99%
Revenue 1Y (TTM)-6.33%
Revenue growth 3Y23.85%
Revenue growth 5YN/A
Sales Q2Q%-95.13%

3.2 Future

  • Based on estimates for the next years, ATRA will show a decrease in Earnings Per Share. The EPS will decrease by -7.25% on average per year.
  • Based on estimates for the next years, ATRA will show a small growth in Revenue. The Revenue will grow by 0.23% on average per year.
EPS Next Y-136.94%
EPS Next 2Y-55.36%
EPS Next 3Y-32.85%
EPS Next 5Y-7.25%
Revenue Next Year-74.32%
Revenue Next 2Y-49.7%
Revenue Next 3Y-25.7%
Revenue Next 5Y0.23%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ATRA Yearly Revenue VS EstimatesATRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 20M 40M 60M 80M 100M
ATRA Yearly EPS VS EstimatesATRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -50 -100

More info and screens

Find the best growth stocksShow best growing peers

3

4. ATRA Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 1.61, the valuation of ATRA can be described as very cheap.
  • Based on the Price/Earnings ratio, ATRA is valued cheaper than 99.42% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 27.42. ATRA is valued rather cheaply when compared to this.
  • ATRA is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 1.61
Fwd PE N/A
ATRA Price Earnings VS Forward Price EarningsATRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

  • 99.22% of the companies in the same industry are more expensive than ATRA, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 1.35
ATRA Per share dataATRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

  • A cheap valuation may be justified as ATRA's earnings are expected to decrease with -32.85% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-55.36%
EPS Next 3Y-32.85%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ATRA Dividend Analysis

5.1 Amount

  • No dividends for ATRA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ATRA Fundamentals: All Metrics, Ratios and Statistics

ATARA BIOTHERAPEUTICS INC

NASDAQ:ATRA (4/24/2026, 8:22:05 PM)

5.01

+0.11 (+2.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-16
Earnings (Next)05-06
Inst Owners45.12%
Inst Owner Change0%
Ins Owners1.65%
Ins Owner Change1.28%
Market Cap40.98M
Revenue(TTM)120.77M
Net Income(TTM)32.69M
Analysts76
Price Target9.52 (90.02%)
Short Float %4.9%
Short Ratio1.21
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)10.23%
Min EPS beat(2)-43.06%
Max EPS beat(2)63.52%
EPS beat(4)3
Avg EPS beat(4)108.57%
Min EPS beat(4)-43.06%
Max EPS beat(4)273.33%
EPS beat(8)5
Avg EPS beat(8)46.32%
EPS beat(12)7
Avg EPS beat(12)23.29%
EPS beat(16)9
Avg EPS beat(16)19.89%
Revenue beat(2)1
Avg Revenue beat(2)52.66%
Min Revenue beat(2)-36.83%
Max Revenue beat(2)142.15%
Revenue beat(4)3
Avg Revenue beat(4)459.46%
Min Revenue beat(4)-36.83%
Max Revenue beat(4)1598.08%
Revenue beat(8)6
Avg Revenue beat(8)237.05%
Revenue beat(12)6
Avg Revenue beat(12)133.78%
Revenue beat(16)8
Avg Revenue beat(16)135.89%
PT rev (1m)0%
PT rev (3m)-52.54%
EPS NQ rev (1m)-132.79%
EPS NQ rev (3m)-119.38%
EPS NY rev (1m)-1068.93%
EPS NY rev (3m)-1606.67%
Revenue NQ rev (1m)-88.02%
Revenue NQ rev (3m)-93.33%
Revenue NY rev (1m)-27.19%
Revenue NY rev (3m)-46.09%
Valuation
Industry RankSector Rank
PE 1.61
Fwd PE N/A
P/S 0.34
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 1.35
EPS(TTM)3.12
EY62.28%
EPS(NY)-1.15
Fwd EYN/A
FCF(TTM)-6.23
FCFYN/A
OCF(TTM)-6.23
OCFYN/A
SpS14.76
BVpS-4.71
TBVpS-4.71
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA 161.54%
ROE N/A
ROCE 989.48%
ROIC 781.69%
ROICexc N/A
ROICexgc N/A
OM 43.53%
PM (TTM) 27.07%
GM 82.44%
FCFM N/A
ROA(3y)-27.86%
ROA(5y)-43.38%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover5.97
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 0.6
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage 183.82
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.82
Quick Ratio 0.82
Altman-Z -125.1
F-Score4
WACC7.08%
ROIC/WACC110.41
Cap/Depr(3y)10.07%
Cap/Depr(5y)43.5%
Cap/Sales(3y)4.82%
Cap/Sales(5y)14.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)124.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.99%
EPS Next Y-136.94%
EPS Next 2Y-55.36%
EPS Next 3Y-32.85%
EPS Next 5Y-7.25%
Revenue 1Y (TTM)-6.33%
Revenue growth 3Y23.85%
Revenue growth 5YN/A
Sales Q2Q%-95.13%
Revenue Next Year-74.32%
Revenue Next 2Y-49.7%
Revenue Next 3Y-25.7%
Revenue Next 5Y0.23%
EBIT growth 1Y167.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-110.29%
EBIT Next 3Y-27.38%
EBIT Next 5Y-19.71%
FCF growth 1Y26.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y25.87%
OCF growth 3YN/A
OCF growth 5YN/A

ATARA BIOTHERAPEUTICS INC / ATRA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ATARA BIOTHERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to ATRA.


What is the valuation status of ATARA BIOTHERAPEUTICS INC (ATRA) stock?

ChartMill assigns a valuation rating of 3 / 10 to ATARA BIOTHERAPEUTICS INC (ATRA). This can be considered as Overvalued.


Can you provide the profitability details for ATARA BIOTHERAPEUTICS INC?

ATARA BIOTHERAPEUTICS INC (ATRA) has a profitability rating of 4 / 10.


What are the PE and PB ratios of ATARA BIOTHERAPEUTICS INC (ATRA) stock?

The Price/Earnings (PE) ratio for ATARA BIOTHERAPEUTICS INC (ATRA) is 1.61 and the Price/Book (PB) ratio is -1.06.